SmartPeptide
Start Free
Fat LossAnimal / preclinical only

5-Amino-1MQ

Small-molecule NNMT inhibitor (NOT a peptide — it's a quinoline derivative). NNMT (nicotinamide N-methyltransferase) is upregulated in obese white adipose tissue. Preclinical studies show 5-Amino-1MQ reduces adipocyte size and improves metabolic markers in obese mice. No human RCTs. Sold as a research chemical.

Educational only — not medical advice. SmartPeptide does not prescribe, diagnose, or treat. Always consult a licensed healthcare provider before using any peptide, supplement, medication, or protocol.

What the research shows

Preclinical evidence in obese mice: reduced fat mass, improved insulin sensitivity, decreased adipocyte size. Mechanism via NNMT inhibition is well-characterized in cell models.

What's still experimental

All human use. Dose, route, duration, drug interactions, and safety are completely uncharacterized in clinical trials.

Anecdotal / community reports

Heavy biohacking-community interest as an 'oral fat-loss peptide.' Self-experimentation logs report variable subjective effects. Quality of grey-market product is highly variable.

Anecdotal reports are NOT scientific evidence. They reflect personal experience and may not generalize.

FDA approval status

Source: openFDA + DailyMed (NIH/NLM)
No FDA-approved drug label exists for “5-Amino-1MQ”. This peptide is not currently approved by the FDA as a finished pharmaceutical product. Any commercial product claiming FDA approval should be treated with suspicion.

Doses studied in research

No established dose range

What published trials tested or FDA-approved labels specify. Reporting research facts — not a SmartPeptide recommendation.

No FDA-approved or established trial dose range for this peptide. Anecdotal ranges discussed in community forums exist but are not supported by published clinical trials, and SmartPeptide will not publish unverified doses.

This is the honest answer for peptides like BPC-157, IGF-1 LR3, MOTS-c, Epitalon and similar research compounds — robust human dose- ranging studies have not been published. Always work with a licensed clinician familiar with experimental peptides if you are considering any use.

FDA enforcement & recalls

Live · openFDA Drug Enforcement API
No FDA enforcement actions (recalls, market withdrawals, safety alerts) on record for “5-Amino-1MQ”. This is the expected baseline for most peptides — the absence of recalls does NOT imply general safety, only that no formal FDA enforcement has been initiated against approved formulations.

Mechanism & targets

ChEMBL · UniProt · Open Targets

Molecule (ChEMBL)

View on ChEMBL
Formula
C12H19N9

Live research

PubMed · ClinicalTrials.gov · Europe PMC · OpenAlex
PubMed papers
151
total
Human studies
0
MeSH: humans
Clinical trials
0
published
Active trials
0
0 total registered

Europe PMC — 2,587,024 additional records

Includes EU/UK studies and PubMed Central full-text articles. Often surfaces research weeks before PubMed indexes it.

Research volume (OpenAlex topic graph)

Total works
8,003,212
all years
Last 5 years
3,023,487
recent activity
Open access
5,922,060
freely readable
OA share
74%
of all works

Human clinical evidence

Semantic Scholar · AI TLDRs · influence-ranked
Semantic Scholar API is currently rate-limited.

Human-study summaries for “5-amino-1-methylquinolinium OR NNMT inhibitor” are available on Semantic Scholar but the shared free-tier API quota is exhausted right now. Try refreshing in a few minutes, or check the PubMed and Europe PMC panels above for the same literature.

Research funding & verification

NIH RePORTER · CrossRef DOI registry

NIH-funded research

U.S. National Institutes of Health
Funded projects
33
all years
Top award sum
$11.1M
aggregate USD
Years covered
20
research span
Largest active / recent grants

Publication landscape

CrossRef · DOI registry
Indexed works (CrossRef)
539,470
all DOIs registered
Retracted papers
0
no retractions on record
Top funders of indexed research
  • National Natural Science Foundation of China13,992 works
  • National Institutes of Health3,592 works
  • Japan Society for the Promotion of Science1,931 works
  • Ministry of Education, Culture, Sports, Science and Technology1,689 works
  • National Key Research and Development Program of China1,684 works
  • National Research Foundation of Korea1,313 works

Funder diversity is a credibility signal. Research concentrated in a single drug company's funding warrants more scrutiny than research funded across NIH, charities, and academic grants.

Preprints — cutting edge

bioRxiv · medRxiv · via Europe PMC

Preprints have NOT been peer-reviewed. They are early research shared by authors before formal validation. Treat findings as preliminary.

Showing 6 of 33,761 preprints indexed by Europe PMC.

Known risks

Essentially unknown in humans. No published Phase 1 data. Source quality / purity for research-chemical supplies is unverifiable without lab analysis.

Reported side effects

Unknown in humans. Animal studies report few acute toxicities at studied doses, but chronic safety is uncharacterized.

FDA adverse event reports (FAERS)

Updated quarterly by FDA
No reports found in the FDA Adverse Event Reporting System for “5-Amino-1MQ”. This is normal for research-only peptides that are not marketed as FDA-approved drugs.

What requires medical supervision

Not approved for any indication. Should only be considered under a clinician familiar with experimental small molecules — though most clinicians would (reasonably) decline.

Questions for your clinician

  • What's the rational evidence base for me to take an unstudied compound?
  • Are FDA-approved obesity medications appropriate first?
  • How would we even monitor for safety?

Editorially curated references

Discussions about 5-Amino-1MQ

Start a discussion
No discussions yet — be the first. Share what you've learned, what worked, what didn't, or a study you want translated into plain English.
See all 5-Amino-1MQ discussions Native, moderated, no buying or selling